Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Subjects - ND
- Conditions
- HIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infection
- Registration Number
- EUCTR2006-005579-16-IT
- Lead Sponsor
- GlaxoSmithKline Research Development
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 728
Subject is 18 years of age 2. Subject is antiretroviral-na ve defined as having ;14 days of prior therapy with any antiretroviral agent . 3. Subject has plasma HIV-1 RNA 1,000 copies/mL at screening. 4. Subject is willing and able to understand and provide written informed consent prior to participation in this study. 5. A female is eligible to enter and participate in the study if she is of a. Non-childbearing potential i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal ; or, b. Child-bearing potential, has a negative pregnancy test at screen and agrees to one of the following methods of contraception any contraception method must be used consistently and correctly, i.e., in accordance with both the approved product label and the instructions of a physician - Complete abstinence from intercourse from 2 weeks prior to administration of the investigational products, throughout the study, and for at least 2 weeks after discontinuation of all study medications - Double barrier method male condom/spermicide, male condom/diaphragm, diaphragm/spermicide . Hormonal contraception will not be permitted in this study - Any intrauterine device IUD with published data showing that the expected failure rate is 1 per year. - Sterilization female subject or male partner of female subject .
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1. Subject is in the initial acute phase of a CDC Clinical Category C infection at Baseline. Subjects may be enrolled provided they are receiving treatment for such infections and are clinically improving at the Baseline visit. 2. Subject is enrolled in one or more investigational drug protocols, which may impact HIV RNA suppression. 3. Subject is either pregnant or breastfeeding. 4. Subject has an estimated creatinine clearance 50 mL/min via the Cockcroft-Gault method Cockcroft, 1976 . This test may be repeated once within the 45-day screening window. 5. Alanine aminotransferase ALT 5 times the upper limit of normal ULN or hepatic impairment as determined by Child-Pugh Score 8805; 5. 6. Subject is receiving, or has received within 90 days prior to screen, any lipid lowering agent, including drugs from the following classes HMG-CoA reductase inhibitors statins , niacin, fibrates, bile acid sequestrants, and/or fish oil supplements. Subjects anticipated to require initiation of therapy with these agents within 12 weeks of Baseline are not eligible to participate. 7. Subject has evidence of genotypic as defined by the current ANRS AC-11 algorithm resistance at screening or prior documented evidence of genotypic and/or phenotypic above threshold for reduced susceptibility resistance to amprenavir/ritonavir, abacavir or lamivudine
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method